X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
male (14) 14
female (13) 13
hematology (11) 11
aged (10) 10
middle aged (10) 10
index medicus (8) 8
oncology (8) 8
adult (7) 7
treatment outcome (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
bortezomib (6) 6
multiple myeloma (6) 6
survival analysis (5) 5
italy (4) 4
melphalan (4) 4
multiple myeloma - drug therapy (4) 4
multiple myeloma - mortality (4) 4
retrospective studies (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
benzamides (3) 3
cancer (3) 3
disease-free survival (3) 3
drug therapy (3) 3
elderly-patients (3) 3
further section (3) 3
imatinib (3) 3
imatinib mesylate (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
prednisone (3) 3
recurrence (3) 3
remission induction (3) 3
thalidomide (3) 3
abridged index medicus (2) 2
acute promyelocytic leukemia (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
beacopp regimen (2) 2
breccia (2) 2
chemotherapy (2) 2
chronic-phase chronic myeloid leukaemia (2) 2
cyclophosphamide - administration & dosage (2) 2
cyclophosphamide - adverse effects (2) 2
deep-vein thrombosis (2) 2
dexamethasone - administration & dosage (2) 2
diseases of the blood and blood-forming organs (2) 2
dosage and administration (2) 2
drug dosages (2) 2
elderly patients (2) 2
follow-up studies (2) 2
gentuzumab ozogamicin (2) 2
health aspects (2) 2
hemic and lymphatic diseases (2) 2
hodgkin lymphoma (2) 2
molecular relapse (2) 2
multiple myeloma, cystic fibrosis, bortezomib (2) 2
myelodysplastic syndromes (2) 2
patients (2) 2
peripheral neuropathy (2) 2
phenotype (2) 2
piperazines - adverse effects (2) 2
piperazines - therapeutic use (2) 2
prednisone - administration & dosage (2) 2
prednisone plus thalidomide (2) 2
prognosis (2) 2
prognostic-factors (2) 2
pyrimidines - adverse effects (2) 2
pyrimidines - therapeutic use (2) 2
refractory hodgkin lymphoma (2) 2
relapsed hodgkin lymphoma (2) 2
response monitoring (2) 2
risk factors (2) 2
safety (2) 2
scoring system (2) 2
simplicity (2) 2
stem-cell transplantation (2) 2
therapy (2) 2
tki switching patterns (2) 2
trial (2) 2
young adult (2) 2
1st-line treatment (1) 1
abnormalities (1) 1
adenocarcinoma - diagnosis (1) 1
adenocarcinoma - therapy (1) 1
adults (1) 1
aged patients (1) 1
aminoglycosides - administration & dosage (1) 1
anemia - etiology (1) 1
anemia, refractory, with excess of blasts - classification (1) 1
anemia, refractory, with excess of blasts - genetics (1) 1
anemia, refractory, with excess of blasts - pathology (1) 1
anemia, sideroblastic - etiology (1) 1
antibodies (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized (1) 1
anticoagulants - adverse effects (1) 1
anticoagulants - therapeutic use (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
Recenti Progressi in Medicina, ISSN 0034-1193, 12/2018, Volume 109, Issue 12, pp. 566 - 569
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5753 - 5753
Abstract Background: Bendamustine is effective as first-line treatment of multiple myeloma (MM) patients, as well as in heavily pre-treated relapsed/refractory... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 3455 - 3455
Abstract Background: Solitary plasmacytoma (SP) is a rare form of plasma cell dyscrasia that represents 2.8-5% of all plasma cell disorders. It is... 
Journal Article
Patient Preference and Adherence, ISSN 1177-889X, 07/2014, Volume 8, pp. 939 - 946
Journal Article
Cadernos de Pesquisa, ISSN 0100-1574, 2014, Volume 44, Issue 153, pp. 486 - 492
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1828 - 1828
Abstract Background Carfilzomib is a novel second generation proteasome-inhibitor with significant anti-MM activity and favorable toxicity profile. In a recent... 
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4056 - 4056
Abstract Abstract 4056 Background: Peripheral neuropathy (PN) and neuropathic pain are common and severe dose-limiting side effects of Bortezomib and/or IMIDs... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 5375 - 5375
Abstract Background The introduction of new agents has substantially changed the management of patients with multiple myeloma (MM). PATIENTS AND METHODS: We... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 175 - 175
Abstract Background Carfilzomib is a novel second generation proteasome-inhibitor with significant anti MM activity and favorable toxicity profile, including... 
Journal Article
Cancer, ISSN 0008-543X, 03/2013, Volume 119, Issue 5, pp. 971 - 977
BACKGROUND: In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP)... 
elderly patients | multiple myeloma | prednisone | bortezomib | melphalan
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2013, Volume 160, Issue 5, pp. 673 - 679
Journal Article
Mediterranean Journal of Hematology and Infectious Diseases, ISSN 2035-3006, 04/2019, Volume 11, Issue 1, p. e2019025
Background and Objectives While tyrosine kinase inhibitors (TKIs) have transformed CP-CML management, limited data exist on their use in clinical practice.... 
Chronic-Phase Chronic Myeloid Leukaemia | TKI switching patterns | Italy | SIMPLICITY | Response Monitoring
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.